

Supplementary Materials

Protective Effects of Astodimer Sodium 1% Nasal Spray Formulation Against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice




Figure S1. A seven-day time course of amount of cytokine/chemokine (pg/mL) in serum of SARS-CoV-2 (USA-WA1/2020) infected K18-hACE2 mice treated with PBS (Group 2.1) or astodimer sodium 1% nasal spray formulation (Group 2.2) via intranasal and intratracheal administration: (a) IL-6 (b) IL-1 α (c) IL-1 β (d) TNF α (e) TGF β (f) MCP-1. Points and error bars represent means \pm SD.




Figure S2. A seven-day time course of amount of cytokine/chemokine (pg/mL) in serum of in K18-hACE2 mice infected with SARS-CoV-2 (USA-WA1/2020) inoculum incubated with PBS (Group 3.1) or astodimer sodium 1% nasal spray (Group 3.2) for 60 minutes prior to neutralisation procedure – virucidal evaluation: (a) IL-6 (b) IL-1 α (c) IL-1 β (d) TNF α (e) TGF β (f) MCP-1. Points and error bars represent means \pm SD.




Figure S3. Amount of cytokine/chemokine in lung and trachea tissue homogenates from SARS-CoV-2 (USA-WA1/2020) infected K18-hACE2 mice treated with PBS (Group 1.1) or astodimer sodium 1% nasal spray (Group 1.2) formulation via intranasal administration: (a) IL-6 (b) IL-1 α (c) IL-1 β (d) TNF α (e) TGF β (f) MCP-1. Columns and error bars represent means \pm SEM. * $p < 0.05$, ** $p < 0.01$, paired t-tests.




Figure S4. Amount of cytokine/chemokine in lung and trachea tissue homogenates from SARS-CoV-2 (USA-WA1/2020) infected K18-hACE2 mice treated with PBS (Group 2.1) or astodimer sodium 1% nasal spray (Group 2.2) formulation via intranasal and intratracheal administration: (a) IL-6 (b) IL-1 α (c) IL-1 β (d) TNF α (e) TGF β (f) MCP-1. Columns and error bars represent means \pm SEM. * $p < 0.05$, ** $p < 0.01$, paired t-tests.